Ovarian Carcinosarcoma
Symptoms, Doctors, Treatments, Advances & More

Ovarian Carcinosarcoma Overview

Save information for later
Sign Up

Learn About Ovarian Carcinosarcoma

What is the definition of Ovarian Carcinosarcoma?
Ovarian carcinosarcoma, also known as a malignant mixed mullerian tumor (MMMT) of the ovary, is a rare, aggressive cancer of the ovary with characteristics of two types of cancer: carcinoma and sarcoma. Because women with this cancer often have no symptoms, more than half of women are diagnosed at an advanced stage. When present, symptoms may include pain in the abdomen or pelvic area, bloating or swelling of the abdomen, quickly feeling full when eating, or other digestive problems. The cause of Ovarian carcinosarcoma is not yet understood.
What are the alternative names for Ovarian Carcinosarcoma?
  • Ovarian carcinosarcoma
  • MMMT of the ovary
  • Malignant mixed Müllerian tumor of the ovary
  • Malignant mixed mullerian tumor of the ovary
  • Ovarian malignant mixed Müllerian tumor
  • Ovarian malignant mixed epithelial mesenchymal tumor
Who are the top Ovarian Carcinosarcoma Local Doctors?
Elite in Ovarian Carcinosarcoma
Dr. Peter Rose
Surgical Oncology
Elite in Ovarian Carcinosarcoma
Dr. Peter Rose
Surgical Oncology
Referral may be required

Cleveland Clinic Main Campus

10201 Carnegie Avenue, 
Cleveland, OH 
866-223-8100
Experience:
49+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Peter Rose is a Surgical Oncologist practicing medicine in Cleveland, Ohio. He has been practicing medicine for over 49 years. Dr. Rose is rated as an Elite provider by MediFind in the treatment of Ovarian Carcinosarcoma. He is also highly rated in 20 other conditions, according to our data. His clinical expertise encompasses Ovarian Cancer, Endometrial Cancer, Ovarian Carcinosarcoma, Salpingo-Oophorectomy, and Hernia Surgery. Dr. Rose is board certified in American Board Of Obstetrics And Gynecology, 1990.

Elite in Ovarian Carcinosarcoma
Elite in Ovarian Carcinosarcoma
Referral may be required

Northwell Health Physician Partners Gynecologic Oncology At New Hyde Park

9 Vermont Drive, 1st Floor, 
New Hyde Park, NY 
516-812-3740
Languages Spoken:
English, Spanish
See accepted insurances
Offers Telehealth

Joan Tymon is an Oncologist practicing medicine in New Hyde Park, New York. Dr. Tymon is rated as an Elite provider by MediFind in the treatment of Ovarian Carcinosarcoma. She is also highly rated in 9 other conditions, according to our data. Her clinical expertise encompasses Ovarian Carcinosarcoma, Ovarian Cancer, Malignant Mixed Mullerian Tumor, Hysterectomy, and Oophorectomy. Dr. Tymon is board certified in American Board Of Obstetrics & Gynecology.

 
 
 
 
Learn about our expert tiers
Learn More
Distinguished in Ovarian Carcinosarcoma
Distinguished in Ovarian Carcinosarcoma
Referral required

Aurora Gynecologic Oncology

8905 W Lincoln Ave, Ste 407, 
West Allis, WI 
414-329-5656
Languages Spoken:
English
See accepted insurances

Scott Kamelle is an Oncologist practicing medicine in West Allis, Wisconsin. Dr. Kamelle is rated as a Distinguished provider by MediFind in the treatment of Ovarian Carcinosarcoma. He is also highly rated in 15 other conditions, according to our data. His clinical expertise encompasses Endometrial Cancer, Ovarian Carcinosarcoma, Sertoli-Leydig Cell Tumor, Ureteroscopy, and Bladder Reconstruction. Dr. Kamelle is board certified in American Board Of Obstetrics & Gynecology, Gynecologic Oncology.

View All Doctors
What are the latest Ovarian Carcinosarcoma Clinical Trials?
An International Multicentric Randomized Phase II Evaluating Dostarlimab in Combination With Niraparib Versus Niraparib Alone Compared to Chemotherapy in the Treatment of Metastatic or Recurrent Endometrial or Ovarian Carcinosarcoma After at Least One Line of Chemotherapy
An International Multicentric Randomized Phase II Evaluating Dostarlimab in Combination With Niraparib Versus Niraparib Alone Compared to Chemotherapy in the Treatment of Metastatic or Recurrent Endometrial or Ovarian Carcinosarcoma After at Least One Line of Chemotherapy
Who is this study for: Patients with metastatic or recurrent endometrial or ovarian carcinosarcoma after at least one line of chemotherapy
Enrollment Status: Recruiting
Publish Date: June 01, 2026
Intervention Type: Drug, Combination product
Study Drug: Niraparib
Study Phase: Phase 2/Phase 3

Summary: Carcinosarcomas (CS) (malignant mixed Müllerian tumors) are highly aggressive and rare tumors with a worldwide annual incidence between 0.5-3.3 cases/100.000 women. Gynecological CS, i.e. ovarian CS (OCS) and uterine CS (UCS), have a 5-year overall survival (OS) \< 10% and a poor prognosis. After initial treatment (surgery +/- adjuvant radiotherapies +/- chemotherapies (CT)), vast majority of pati...

Match to trials
Find the right clinical trials for you in under a minute
Get started
MC220601, Folate Receptor Alpha Dendritic Cells (FRαDCs) Plus Pembrolizumab for Patients With Advanced Stage Ovarian Cancer (FRAPPE)
MC220601, Folate Receptor Alpha Dendritic Cells (FRαDCs) Plus Pembrolizumab for Patients With Advanced Stage Ovarian Cancer (FRAPPE)
Enrollment Status: Recruiting
Publish Date: April 06, 2026
Intervention Type: Procedure, Biological
Study Phase: Phase 1/Phase 2

Summary: This phase I/II trial tests the safety, side effects, best dose, and effectiveness of multi-epitope folate receptor alpha-loaded dendritic cell vaccine (FRalphaDC) with pembrolizumab in treating patients with ovarian, fallopian tube, or primary peritoneal cancer (collectively known as ovarian cancer) that that has come back (after a period of improvement) (recurrent). Ovarian cancer is the most le...

View All Clinical Trials
Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center